Aberrant methylation of DACT1 and DACT2 are associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma

Yan-li Guo, Bao-En Shan*, Wei Guo*, Zhi-Ming Dong, Zhen Zhou, Su-Peng Shen, Xin Guo, Jia Liang and Gang Kuang

Abstract

Background: The DACT (Dishevelled-associated antagonist of β-catenin) family of scaffold proteins may play important roles in tumorigenesis. However, the epigenetic changes of DACT1, 2, 3 and their effect on esophageal squamous cell carcinoma (ESCC) have not been investigated so far. The aim of this study was to investigate the promoter methylation and expression of DACT family, in order to elucidate more information on the role of DACT with regard to the progression and prognosis of ESCC.

Methods: MSP and BGS methods were respectively applied to examine the methylation status of DACT; RT-PCR, Western blot and immunohistochemistry methods were respectively used to determine the mRNA and protein expression of DACT; MTT, Colony-formation and Wound-healing assay were performed to assess the effect of DACT1 and DACT2 on proliferation and migration of esophageal cancer cells.

Results: Frequent reduced expression of DACT1, DACT2 and DACT3 were found in esophageal cancer cell lines and the expression levels of DACT1 and DACT2 were reversed by S-Aza-Dc. Decreased mRNA and protein expression of DACT1 and DACT2 were observed in ESCC tumor tissues and were associated with the methylation status of transcription start site (TSS) region. The hypermethylation of CpG islands (CGI) shore region in DACT1 was observed both in tumor and corresponding adjacent tissues but wasn't related to the transcriptional inhibition of DACT1. The methylation status of TSS region in DACT1 and DACT2 and the protein expression of DACT2 were independently associated with ESCC patients' prognosis.

Conclusions: The TSS region hypermethylation may be one of the main mechanisms for reduced expression of DACT1 and DACT2 in ESCC. The simultaneous methylation of DACT1 and DACT2 may play important roles in progression of ESCC and may serve as prognostic methylation biomarkers for ESCC patients.

Keywords: Esophageal squamous cell carcinoma, DACT gene, Methylation, Prognosis
Background
Esophageal cancer is the eighth most common malignancy in the world and the overall prognosis for esophageal cancer patients is very poor [1–3]. According to the WHO report in 2012, the world's new cases of esophageal cancer were 455,000, and 223,000 of them occurred in China, accounting for 49% [4]. In China, esophageal squamous cell carcinoma (ESCC) was the dominant histological type of esophageal malignances. Based on two national mortality surveys conducted in 1970s and 1990s, ESCC has a striking geographic distribution in China, with higher prevalence in Taihang mountain areas of North China [5]. There was also a strong tendency toward familial aggregation of ESCC in these high-risk areas [6], suggesting that multiple genetic and epigenetic events may contribute to the occurrence and progression of ESCC. However, the precise molecular mechanisms of the development and progression of ESCC still remained unknown. Therefore, additional elucidation of the molecular mechanisms involved in ESCC and the discovery of early detect biomarkers are urgently needed for more effective chemoprevention or treatment.

The DACT (Dishevelled-associated antagonist of β-catenin) family of scaffold proteins, including DACT1, DACT2 and DACT3, were isolated by a screen for proteins interacting with Dishevelled protein central to Wnt signaling [7–9]. DACT encode a series of vertebrate intracellular proteins those can regulate intercellular signaling pathways [10–12]. According to previous reports, DACT proteins act as tumor suppressors in different tumor types [13–15]. In addition, decreased expression and promoter hypermethylation of DACT1 and DACT2 have been found in some primary tumors and tumor cell lines, including hepatocellular carcinoma [15], breast cancer [16], lung cancer [17], colorectal cancer [18] and some other cancers. However, Schussel et al. [19] showed quite a different result which the promoter methylation of DACT1 and DACT2 may not be a common event in oral squamous cell carcinoma. Although the promoter of DACT3 also has a large CpG Island, but the study in colorectal cancer indicates that the histone modification, rather than the aberrant, may be the main regulated mechanism for inactivation of this gene [18]. To our best knowledge, the regulation mechanism of DACT1, DACT2 and DACT3 and their function in ESCC remains unknown. In the present study, we attempted to detect the role and methylation status of DACT1, DACT2 and DACT3 in ESCC, and to elucidate the effect of their methylation status on progression / prognosis of ESCC patients.

Methods
Cell culture and treatment
The human esophageal cancer cell lines TE1, TE13, T.Tn and Eca109 were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin. Treatment of these four cells with DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-Aza-Dc, 5 μmol/L, Sigma, St Louis, MO, USA) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA,0.3 μmol/L, Cayman Chemical Co, Ann Arbor, MI, USA) was performed as previously reports [20, 21]. Control cells received no drug treatment. DNA, RNA and protein were isolated from these cells.

Patients and specimens
One hundred fifty-nine paired primary tumor and corresponding adjacent non-cancerous tissues of ESCC were collected from the Fourth Affiliated Hospital, Hebei Medical University between the years of 2005 and 2009. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hebei Medical University Fourth Affiliated Hospital, and the informed consent was obtained from all of the patients. All study subjects were ethnically homogeneous Han nationality and were from the same areas, which were the high-risk areas of upper gastrointestinal cancers (UGIC) in Hebei province. The incidence of UGIC in this area was over one hundred per one hundred thousands [22, 23]. Complete clinicopathologic characteristics and UGIC family history of these cases were available before operation and during follow-up. Individuals with at least one first-degree relative or at least two second-degree relatives having esophageal/-cardia/gastric cancer were defined as having family history of UGIC. Distribution of clinicopathological data in the study cohort was shown in Table 1. For this study, all of the subjects were re-examined and confirmed by professional pathologists for histopathological diagnosis. All the esophageal cancer were squamous cell carcinoma and the adjacent non-cancerous tissues were normal tissues or hyperplasia tissues, which confirmed by microscope examination. The survival data were ascertained through the Tumor Registry and Hospital chart review. Fourteen patients were lost to follow up.

Stable gene transfections
Transfection was done using FuGENE HD transfection reagent (Roche, Swiss) as recommended by the manufacturer’s instructions. Full-length DACT1 and DACT2 cDNA were cloned into pcDNA3.1 and pCMV6 vector. Then, exponentially grown TE1 and TE13 cells were transfected with DACT1 and DACT2 expression plasmid (pcDNA3.1-DACT1 and pCMV6-DACT2) or the relevant empty
vector (pcDNA3.1/TE1 and pCMV6/TE1) as control. The resistant cell clones were selected with G418 expanded for further characterization.

Cell proliferation assay
Cell proliferation was measured with MTT assay. The TE1 or TE13 cells, the stable transfected cells (pcDNA3.1-DACT1/TE1,TE13 and pCMV6-DACT2/TE1,TE13) and the cells treated with 5-Aza-Dc for 72 h were seeded in 24-well plates at the concentration of $2 \times 10^5$ per well and allowed to form a confluent monolayer for 24 h, and then scratched with a pipette tip and washed to remove floating cells. Cells were photographed at the same field every 2 h.

Colony formation assay
For colony assay, The TE1 or TE13 cells, the stable transfected cells (pcDNA3.1-DACT1/TE1,TE13 and pCMV6-DACT2/TE1,TE13) and the cells treated with 5-Aza-Dc for 72 h were seeded at density 500 cells/35 mm dish (three dishes/group), and incubated in normal growth medium two weeks later, cell colonies were stained with hematoxylin and counted.

Table 1 Protein expression of DACT1, DACT2 and DACT3 in ESCC Cases

| Group          | N | DACT1 Protein positive n (%) | p    | DACT2 Protein positive n (%) | p    |
|----------------|---|-----------------------------|------|-----------------------------|------|
| Age            |   |                             |      |                             |      |
| <60            | 74 | 44(59.5%)                   | 0.935| 37(50.0%)                   | 0.337|
| ≥60            | 85 | 50(58.8%)                   |      | 49(57.6%)                   |      |
| Gender         |   |                             |      |                             |      |
| Male           | 93 | 56(60.2%)                   | 0.739| 49(52.7%)                   | 0.674|
| Female         | 66 | 38(57.6%)                   |      | 37(56.1%)                   |      |
| Histological grade | |                             |      |                             |      |
| Well/moderate  | 98 | 58(59.2%)                   | 0.983| 54(55.1%)                   | 0.483|
| Poor           | 61 | 36(59.0%)                   |      | 32(52.5%)                   |      |
| clinical stage |   |                             |      |                             |      |
| I + II         | 86 | 59(68.6%)                   | 0.008| 53(61.6%)                   | 0.038|
| III + IV       | 73 | 35(47.9%)                   |      | 33(45.2%)                   |      |
| Lymph node     |   |                             |      |                             |      |
| +              | 121| 66(54.5%)                   | 0.036| 57(47.1%)                   | 0.105|
| -              | 38 | 28(73.7%)                   |      | 29(76.3%)                   |      |
| Family history of UGIC | |                             |      |                             |      |
| +              | 61 | 31(50.8%)                   | 0.093| 26(42.6%)                   | 0.022|
| -              | 98 | 63(64.3%)                   |      | 60(61.2%)                   |      |

Wound-healing assay
The TE1 or TE13 cells, the stable transfected cells (pcDNA3.1-DACT1/TE1,TE13 and pCMV6-DACT2/TE1,TE13) and the cells treated with 5-Aza-Dc for 72 h were seeded in 24-well plates at the concentration of $2 \times 10^5$ per well and allowed to form a confluent monolayer for 24 h, and then scratched with a pipette tip and washed to remove floating cells. Cells were photographed at the same field every 2 h.

DACT1, DACT2, DACT3 mRNA expression via semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and quantitative real-time RT-PCR assays
Total RNA was isolated from cell lines and tissues by Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Agarose gel electrophoresis and spectrophotometric analysis (A260: 280 nm ratio) were used to evaluate RNA quality and quantity. RT-for-PCR kit (Clontech, Palo Alto, CA) with random priming as recommended in the protocol provided. All primers and reaction conditions are listed in Additional file 1: Table S1. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal control. For RT-PCR, the PCR products were separated in 2% agarose gel in electrophoresis and visualized with ethidium bromide staining, and quantified using an image analysis system (Gel work-2ID). Real time PCR reactions were performed by the Stepone Plus Thermal Cycler (Applied Biosystems, Foster City, CA, USA) and SYBR green PCR Master Mix (Life Technology, Foster City, CA, USA). The expression levels of target genes were normalized with GAPDH using the 2$^{-\Delta\Delta CT}$ method [24]. The reaction was repeated in triplicate with each of the samples for quality control.

Western blot analysis
Western blot was performed according to previous report [25]. Whole cell lysates from cell lines were prepared by lysing the cells in ice-cold RIPA buffer. The protein concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA), and then, equal amount of proteins were separated by SDS-PAGE and electroblotted onto PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked in 5% nonfat milk and incubated with Rabbit anti-human polyclonal antibody for DACT1 (1 μg/ml, ab72078, Abcam, UK) and DACT2 (2 μg/ml, ab79042, Abcam, UK), and mouse anti-human monoclonal antibody for β-actin (1:5000 dilution, ab6276, Abcam, UK) and visualization with enhanced chemiluminescence (ECL) detection reagents (Beyotime, Haimen, Jiangsu, China).
DACT1, DACT2 protein expression via immunohistochemical staining (IHC)

The protein expression of DACT1, DACT2 and DACT3 in tumor and corresponding adjacent tissues of ESCC was detected using the immunostaining method of avidin-biotin complex immunoperoxidase [26]. After blocking of endogenous peroxidase and non-specific reactions, the slides were incubated with rabbit anti-human polyclonal antibody for DACT1 (1:100 dilution, abcam, UK), DACT2 (1:100 dilution, abcam, UK) and DACT3 (1:50 dilution, AmyJet Scientific), and then incubated with biotinylated secondary antibody and ABC reagent. 3, 3′-Diaminobenzidine (Sigma, St Louis, MO) was used as the chromogen, and counterstaining was done using hematoxylin. In negative controls, the primary antibody was replaced with non-immune serum for the negative control. Slides with positive staining of DACT1, DACT2 and DACT3 were used as positive control. Protein expression of DACT1, DACT2 and DACT3 were evaluated according to a scoring method reported previously [26]. Scoring accounted for both intensity and the percentage of positive cells. All slides were examined and scored by three independent observers, who were blinded to the clinical data.

Methylation analysis of DACT via methylation-specific polymerase chain reaction (MSP) and bisulfite genomic sequencing (BGS) methods

Total DNA was isolated from cell lines using DNAzol (Invitrogen, Carlsbad, CA, USA) and the genomic DNA from tissues of ESCC was prepared using the Proteinase K digestion method. Genomic DNA was treated with Epitect Fast Bisulfite Conversion Kits (Qiagen, Germany) according to the manufacturer’s instructions. Unmethylated cytosines was converted to uracil by bisulfite treatment, whereas methylated cytosine couldn’t be converted and remained as cytosine. Based on this potential difference in the DNA sequence between methylated and unmethylated alleles after bisulfite treatment, we designed MSP primers to analyze two regions of DACT1, and one region of DACT2 and DACT3. One of the regions in DACT1 was encompassing TSS (region 2, from −16 to 105 bp) and the other was located in the CGI shore (region 1, from −540 to −419 bp), which was the flank of the traditional CpG islands and had relatively low CpG density. The methylation status of DACT2 (from −30 to 126 bp) and DACT3 (from −154 to 28 bp) were determined in the region encompassing TSS (Fig. 1a, b, c). The MSP products were analyzed on 2% agarose gels with ethidium bromide and visualized under UV illumination. Genomic DNA, which was treated by CpG methyltransferase (Sss I) following the manufacturer’s directions (New England BioLabs, Inc, Beverly, MA), was used as positive control. Water blank was used as a negative control. Every sample was repeated methylation analysis in duplicate in order to ensure the quality control. For BGS, primers were designed to recognize sodium bisulfite converted DNA and encompassing the MSP regions (DACT1, BGS region 1 from −573 to −382 bp, BGS region 2 from −196 to −376 bp; DACT2, from −30 to −226 bp; DACT3, from −349 to −148 bp) (Fig. 1a, b, c). The primer sequences of DACT1, DACT2, DACT3 and PCR conditions (product size and annealing temperatures) were shown in Additional file 1: Table S1. The target fragment of PCR products for BGS were purified and cloned into pGEM-T vectors (Promega, San Luis Obispo, CA) and 10 clones of each specimen were sequenced by automated fluorescence-based DNA sequencing.

Statistical analysis

Statistical analysis was performed using SPSS19.0 software package (SPSS Company, Chicago, IL). The methylation frequency of DACT1, DACT2, DACT3 between ESCC and corresponding adjacent tissues were compared using Chi-square test. The mRNA expression of DACT genes was expressed as the mean ± standard deviation and the means were compared using the Student’s t test. Kaplan–Meier survival curves were constructed and the Log-rank tests were used as needed for the univariate comparison of DACT expression and methylation categories. Cox’s multivariate test was used to adjust for potentially confounding variables and to evaluate the role of DACT as an independent predictor for patient prognosis. Two-sided tests were used to determine significance and P values < 0.05 was regarded as statistically significant for all statistic tests.

Results

Frequent silencing of DACT1, DACT2 and DACT3 in esophageal cancer cell lines

The mRNA expression of DACT1, DACT2 and DACT3 were examined in four esophageal cancer cell lines by RT-PCR and qRT-PCR methods. The mRNA expression of DACT1 was silenced in TE13, T.Tn cell lines and reduced in TE1, Eca109 cell lines; the mRNA expression of DACT2 was silenced in TE1, T.Tn, Eca109 cell lines and reduced in TE13 cell line; while the mRNA expression levels of DACT3 remained relatively weak in all four cell lines (Fig. 1d, e, f, g).

Up-regulation of DACT1 and DACT2, but not DACT3, by 5-Aza-Dc treatment in esophageal cancer cell lines

In order to clarify the possible epigenetic mechanism of down-regulation of DACT1, DACT2 and DACT3 expression (such as methylation and acetylation), we further detected the mRNA expression of DACT1,2,3 in cell lines after 5-Aza-Dc (DNA methyltransferase inhibitor) or TSA (histone deacetylase inhibitor) treatment. As shown in Fig. 1d, e, f, g, the mRNA expression of DACT1 and
DACT2 were all significantly increased in four esophageal cancer cells after treatment with 5-Aza-Dc, but not with TSA. However, DACT3 mRNA was not significantly upregulated after treatment with 5-Aza-Dc or TSA in four esophageal cancer cell lines.

The aberrant promoter methylation of DACT1 and DACT2 induce down-regulation of their mRNA expression in esophageal cancer cell lines

To investigate whether the silencing of DACT1, 2, 3 were associated with their hypermethylation, the Meth-Primer program [27] and the CpG island searcher [28] were firstly used to analyze the CpG islands within the sequence of DACT genes. As shown in Fig. 1, DACT1, DACT2 and DACT3 were all shown to have the CpG islands. MSP results were shown in Fig. 1h, complete methylation was found in TE13 and T.TN cell lines and incomplete methylation was observed in TE1 and Eca109 cell lines in the two regions of DACT1. The complete methylation of DACT2 was detected in TE1, T.TN, Eca109 cell lines and incomplete methylation was detected in TE13 cell lines. No methylated bands of DACT3 were detected in all four cell lines. The BGS assay was used to reveal dense methylation of every CpG sites. As shown in Fig. 1i, the methylation frequency of DACT1 CpG sites were higher in TE13 and T.TN cell lines than those in TE1 and Eca109 cell lines, especially the sites which were contained in the primers. The methylation frequency of DACT2 CpG sites were higher in TE1, T.TN and Eca109 cell lines than those in TE13 cell lines, especially the sites which were contained in the primers. No methylation was found of DACT3 in these four cell lines. The results indicated that the MSP assay results accurately represent DACT1, DACT2 and DACT3 methylation status in these cell lines. After treatment with 5-Aza-Dc, demethylation of DACT1 and DACT2 were observed in these cells, together with the results of DACT1 and DACT2 expression was restored.
or increased after 5-Aza-Dc treatment, indicating that DACT1 and DACT2 expression was regulated by the methylation status of the genes.

**Inhibition of proliferation and migration in TE1 and TE13 Cell lines after restoration of DACT1/DACT2 or treatment with 5-Aza-Dc**

TE1 and TE13 cells, which demonstrated low or negative expression of DACT1 and DACT2 genes, were adopted to transfected with DACT1 or DACT2 plasmid and investigate effect of DACT1 or DACT2 on the cell proliferation using MTT and Colony-formation assays respectively. As shown in Fig. 2, stable transfection of DACT1/DACT2 or treatment with 5-Aza-Dc resulted in significant inhibition of the proliferation index and reduction of colony numbers in TE1 and TE13 cell lines. The Wound-healing assay was further employed to evaluate the effect of DACT1 and DACT2 on cell migration. Cell migration ability was significantly decreased at 12, 24, 36 and 48 h after transfection with DACT1/DACT2 or treatment with 5-Aza-Dc (Fig. 2d). These results suggested that DACT1 and DACT2 may act as tumor suppressor genes in esophageal cancer through inhibition of cell proliferation and migration.

**Decreased mRNA and protein expression of DACT1, DACT2, DACT3 in ESCC**

DACT1, DACT2, DACT3 mRNA expression in ESCC tissues were reduced significantly compared with those in corresponding adjacent non-cancerous tissues ($t_{DACT1} = 16.548, P < 0.001; t_{DACT2} = 7.236, P < 0.001; t_{DACT3} = 7.124, P < 0.001$) (Fig. 3a, b). IHC method was used to evaluate the protein expression of DACT1, DACT2, and DACT3 in ESCC tissues. The pattern of immunohistochemical staining of them was cytoplasmic (Fig. 3c). The frequency of DACT1, DACT2, DACT3 positive expression in tumor tissues was significantly lower than that in corresponding adjacent non-cancerous tissues (Fig. 3d; $P < 0.001$). When stratified for clinicopathologic characteristics, DACT1 and DACT2 mRNA and protein expression was associated with clinical stage, Lymph node metastasis and UGIC family

---

**Fig. 2** The effect on cell proliferation, colony formation and immigration abilities in TE1 and TE13 cell lines after treated with 5-Aza-dC or stable transfected of DACT1/DACT2. **a** The protein expression of DACT1 and DACT2 in TE1 or TE13 cells after stable transfected with DACT1/DACT2 plasmid or treated with 5-Aza-dC using western-blot method. **b** The results of MTT assay in treated or untreated TE1/TE13 cells with 5-Aza-dC or the stable transfected TE1/TE13 cells; **c** The results of colony formation assays in treated or untreated TE1/TE13 cells with 5-Aza-dC or the stable transfected TE1/TE13 cells; **d** The relative scratch width of treated or untreated TE1/TE13 cells or the stable transfected TE1/TE13 cells detected by Wound healing analysis. The initial width of the scratch was as 1.
history ($P < 0.05$), but not with age, gender, histological grade (Table 1; Fig. 3e, f).

Aberrant methylation of DACT1 and DACT2 in ESCC clinical specimens

The methylation analysis of DACT1, DACT2 and DACT3 were successfully performed using MSP method in all specimens (Fig. 3g). The methylation frequency of DACT1 was different in two regions (Fig. 3h). Of primary ESCC and corresponding non-cancerous tissues, hypermethylation was observed in 54.1% (86/159) and 43.4% (69/159) at region1, 47.8% (76/159) and 16.4% (26/159) at region2, respectively. The methylation frequency of DACT1 in the region1 and region 2 were all higher than those in corresponding adjacent tissues, however, only region 2 showed the statistical difference ($P_{\text{region1}} > 0.05$; $P_{\text{region2}} < 0.001$; Fig. 3h). The methylation frequency of DACT2 was 52.2% (83/159) in tumor tissues, which was higher than that in corresponding adjacent tissues (21.4%, 34/159, $P < 0.001$; Fig. 3h). The methylation frequency of DACT3 was very low both in ESCC and corresponding adjacent tissues (3.8 and 5.7%; $P = 0.598$) (Fig. 3h).

When stratified for clinicopathologic characteristics, the methylation status of region1 in DACT1 was not associated with any characteristic, and the TSS-region in DACT1 (region2) and DACT2 were only associated with...
UGIC family history. But the simultaneous methylation frequency of DACT1 (region2) and DACT2 were associated with clinical stage, LN metastasis and UGIC family history (Table 2).

Association between expression and methylation status of DACT1, DACT2
As show in Fig. 3i and Table 3, the mRNA and protein expression of DACT1, DACT2 in ESCC tissues with hypermethylation of TSS-region were significantly reduced compared to those in ESCC tissues without methylation of this region ($P < 0.05$); However, the mRNA and protein expression of DACT1 was not different between the ESCC tissues with or without hypermethylation of CGI-shore region (region1) ($P > 0.05$). The results indicated that the reduced expression of DACT1 and DACT2 were associated with methylation status of the TSS-region, and the methylation status of CGI-shore region was not associated with the transcriptional inhibition of DACT1.

Survival analysis of DACT1 and DACT2 in ESCC patients
As show in Fig. 4a and b, DACT1 and DACT2 protein expression were positively correlated with ESCC patients’ survival ($P_{DACT1} < 0.001$, $P_{DACT2} = 0.001$, Log-rank test). The simultaneous positive expression of DACT1 and DACT2 showed the best prognosis ($P < 0.001$, Log-rank test, Fig. 4c). The methylation status of region1 in DACT1 was not correlated with ESCC patients’ survival ($P = 0.105$, Log-rank test; Fig. 4d) and TSS-region methylation status of DACT1 and DACT2 were inversely correlated with ESCC patients’ survival ($P_{DACT1} < 0.001$, $P_{DACT2} < 0.001$, Log-rank test; Fig. 4e, f). Furthermore, the ESCC patients with simultaneous methylation of DACT1 and DACT2 showed worst prognosis ($P < 0.001$, Log-rank test; Fig. 4g). ESCC patients in stage III / IV or with positive UGIC family history, and with DACT1 or DACT2 methylation showed poor prognosis (Fig. 4h and i, $P < 0.001$, Log-rank test). To determine which variables were independent predictors of ESCC patients’ survival, a multivariate analysis was performed using COX proportional hazard regression model. The results indicated that the methylation status of TSS-region in DACT1 or DACT2, the protein expression of DACT2, TNM stage and UGIC family history were independently associated with ESCC patients’ survival (Table 4).

### Table 2 Methylation status of DACT1 and DACT2 in ESCC cases

| Group         | N  | DACT1 (region 1) M (%) | p    | DACT1 (region 2) M (%) | p    | DACT2 M (%) | p    | Simultaneous methylation of DACT1 and DACT2 M (%) | p    |
|---------------|----|------------------------|------|------------------------|------|-------------|------|---------------------------------------------|------|
| Age <60       | 74 | 39 (52.7%)             | 0.744| 32 (43.2%)             | 0.283| 39 (52.7%)  | 0.906| 23 (31.1%)                                  | 0.574|
| ≥60           | 85 | 47 (55.3%)             | 0.457| 44 (51.8%)             | 0.151| 47 (50.5%)  | 0.618| 35 (37.6%)                                  | 0.550|
| Gender Male   | 93 | 48 (51.6%)             | 0.457| 40 (43.0%)             | 0.151| 47 (50.5%)  | 0.618| 35 (37.6%)                                  | 0.550|
| Female        | 66 | 38 (57.6%)             | 0.457| 36 (54.5%)             | 0.457| 36 (54.5%)  | 18 (27.3%) |  |
| Histological grade Well/moderate | 98 | 49 (50.0%) | 0.190 | 41 (41.8%) | 0.056 | 46 (46.9%) | 0.092 | 28 (28.6%) | 0.106 |
| Poor          | 61 | 37 (60.7%)             | 0.052| 35 (57.4%)             | 0.060| 37 (60.7%)  | 25 (41.0%) |  |
| Clinical stage I + II | 86 | 46 (53.5%) | 0.869 | 35 (40.7%) | 0.052 | 39 (45.3%) | 0.060 | 22 (25.6%) | 0.015 |
| III + IV      | 73 | 40 (54.8%)             | 0.869| 41 (56.2%)             | 0.445| 44 (60.3%)  | 32 (43.8%) |  |
| Lymph node +  | 121| 70 (57.9%)             | 0.089| 63 (52.1%)             | 0.055| 67 (55.4%)  | 0.153| 48 (39.7%)                                  | 0.001|
| -             | 38 | 16 (42.1%)             | 13 (34.2%) | 16 (42.1%) | 4 (10.5%) |  |
| Family history of UGIC +       | 61 | 38 (62.3%) | 0.010 | 36 (59.0%) | 0.025 | 40 (65.6%) | 0.008 | 29 (47.5%) | 0.004 |
| -             | 98 | 48 (49.0%)             | 0.010| 40 (40.8%)             | 0.072| 43 (43.9%)  | 25 (25.5%) |  |

**M** methylation, **U** unmethylation

### Table 3 Correlation between the methylation status of DACT1, DACT2 and its protein expression in ESCC cases

| Gene            | Positive protein expression (%) | $P$  |
|-----------------|---------------------------------|------|
|                 | M group                         | U group |
| DACT1 (region 1)| 53.5% (46/86)                   | 65.8% (48/73) | 0.117 |
| DACT1 (region 2)| 30.3% (23/76)                   | 85.5% (71/83) | <0.001 |
| DACT2           | 34.9% (29/83)                   | 75.0% (57/76) | <0.001 |

**M** methylation, **U** unmethylation
Discussion
In the present study, we found the expression of DACT1, DACT2 and DACT3 were frequently silenced or decreased in esophageal cancer cell lines. Up-regulation of DACT1 and DACT2 but not DACT3 after treatment with 5-Aza-Dc, inferring that DNA methylation may be the main regulatory mechanism for the inactivation of DACT1 and DACT2 but not DACT3 in esophageal cancer cell lines, which further confirmed by direct BGS and MSP analysis of promoter methylation status of DACT1, 2, 3. However, the mRNA expression of the three genes was not significantly up-regulated after treatment with TSA in esophageal cancer cell lines, indicating that histone acetylation may not play crucial roles...
in the inactivation of DACT1, DACT2 and DACT3. The similar results were observed in other carcinomas such as DACT1 in breast cancer [16] and DACT2 in hepatocellular carcinoma [15], gastric cancer [29], lung cancer [17], colon cancer [13], and also in esophageal cancer [30]. But the result about DACT3 was different from the previous studies. The histone modification may be the main regulated mechanism of DACT3 in colorectal cancer [18]. The difference may partly due to the fact that histone modification has the tumor cell specific and the precise mechanism of this gene inactivation need to be further studied. In addition, the inhibition of proliferation and migration was further detected in TE1 and TE13 cells after treatment with 5-Aza-Dc or stable transfection of DACT1 or DACT2 plasmid, indicating the tumor suppressor role of DACT1 and DACT2 in esophageal cancer cell lines.

Aberrant methylation of CpG islands in gene promoter has been well-established as a major mechanism for the inactivation of tumor suppressor genes in tumorigenesis [31–33]. The hypermethylation of DACT1 in the region near TSS within CpG islands was detected in multiple breast cancer cell lines and primary breast tumors, and the methylation status in this region was a main epigenetic mechanism of DACT1 silencing in breast cancer [16]. Meanwhile, recent studies points out that DNA methylation can directly silence genes with non-CpG islands, such as CGI shore [34, 35]. The aberrant methylation of DACT1 in CGI shore region had been detected in primary gastric cancer and the methylated CpG site count in this region had the significant applicability for prognosis evaluation of gastric cancer patients [36]. Two regions including TSS-region and CGI shore-region were selected to analyze the methylation status of DACT1 in present study. The TSS-region methylation frequency of DACT1 in tumor tissues was significantly higher than that in adjacent tissues and was associated with the decreased mRNA and protein expression of DACT1. The methylation frequency of CGI shore in DACT1 was higher both in tumor and adjacent tissues. These results suggested that hypermethylation of TSS-region was more cancer-specific and was associated with the transcriptional inhibition of DACT1. The TSS-region may be regarded as the critical CpG region of DACT1. The CGI shore-region was more likely to be methylated but may be not necessary for the tumor formation. The TSS-region was selected to analyze the methylation status of DACT2 and there was a significant concordance between the hypermethylation of this gene and its reduced expression in the present study. By using the same MSP primers as we used in this study, Yu et al. [29] found DACT2 was frequently methylated in human gastric cancer and aberrant methylation may be a main mechanism of DACT2 inactiviton. The similar results were also reported in hepatocellular carcinoma [15], lung cancer [17], colon cancer [13] and also in esophageal cancer [30]. When stratified for clinicopathologic characteristics, the methylation status of DACT1 or DACT2 was only associated with UGIC family history, but the simultaneous methylation of DACT1 and DACT2 were associated with clinical stage, LN metastasis and UGIC family history, suggesting that multiple gene methylation may be an ideal cancer biomarker in progression of ESCC and may have definite value on estimating prognosis of ESCC patients.

The relationship between DACT1/DACT2 protein expression, methylation status and the 5-year overall survival rate was further analyzed to evaluate their value in ESCC patients’ prognosis. In the present study, we showed that protein expression and methylation status of DACT1 and DACT2 were significantly and directly correlated with ESCC patients’ survival, suggesting that the inactivation of DACT1 and DACT2 via hypermethylation may confer a growth advantage in ESCC. Therefore, the hypermethylation and inactivation of DACT1 and DACT2 may be considered to be the poor prognostic factors to ESCC patients. But the methylation status of CGI shore-region in DACT1 was not associated with ESCC patients’ survival, mainly due to the reason that this region was not the critical CpG region of DACT1. This result was different from a previous study [36] and the further studies with a larger number of patients may be needed to verify the results. Furthermore, the survival rate of ESCC was closely associated with the stage in which the malignancy is diagnosed [37]. The stage III/IV ESCC patients with DACT1 or DACT2 methylation showed the worse survival, which further indicated the methylation status of DACT1 and DACT2 could be considered as the useful markers for evaluating the prognosis of ESCC. UGIC family history was one of the important factors on the occurrence of ESCC in the high incidence regions of North China [6, 23, 38]. In the present study, the ESCC patients both with positive UGIC family history and DACT1/DACT2 methylation had been showed the worst survival, indicating the poorer prognosis of DACT1/DACT2 methylation in the

| Variable                              | B    | SE   | P      | Odds ratio (95% CI) |
|---------------------------------------|------|------|--------|-------------------|
| MSP1 methylation of DACT1             | -0.240 | 0.215 | 0.265 | 0.787(0.516–1.200) |
| MSP2 methylation of DACT1             | 0.744 | 0.333 | 0.026 | 2.104(1.095–4.043) |
| methylation of DACT2                  | 1.257 | 0.288 | 0.000 | 3.515(1.998–6.183) |
| DACT1 protein                         | 0.520 | 0.298 | 0.081 | 1.681(0.937–3.016) |
| DACT2 protein                         | -0.804 | 0.261 | 0.002 | 0.448(0.269–0.747) |
| TNM stage                             | 1.533 | 0.222 | 0.000 | 4.632(3.000–7.152) |
| Family history of UGIC                | 0.737 | 0.207 | 0.000 | 2.089(1.391–3.137) |
high risk populations. In multivariate analysis, the methylation status of TSS-region in DACT1 and DACT2, negative expression of DACT2, tumor stage, and positive UGIC family history provided independent predictive information on ESCC patients' poor survival.

Conclusion

In conclusion, the present study suggests that the TSS region hypermethylation may be one of the main mechanisms for reduced expression of DACT1 and DACT2 in ESCC. The CGI shore region in DACT1 is more likely to be methylated but is not cancer-specific and isn't related to the transcriptional inhibition of DACT1. The simultaneous methylation of DACT1 and DACT2 may play important roles in progression of ESCC, and may serve as prognostic biomarkers for ESCC patients.

Additional file

**Additional file 1: Table S1.** Primer sequences, annealing temperature and product size of DACT gene Family. (DOC 56 kb)

Acknowledgements

The authors thank all subjects who participated in this study.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81472335, to W.G; No. 81572441, to Z.M.D); Natural Science Foundation of Hebei Province of China (No.H2013206315, to Y.L.G; No. H2015206196, to W.G; No. H2015206420, to Z.M.D); The focal point Project of Hebei medical research (No.20130545, to Y.L.G).

Availability of data and materials

Data and materials related to this work are available upon request.

Authors' contributions

BS and WG designed the study and applied for Research Ethics Board approval. YG performed the experiments, analyzed the data and prepared the manuscript. ZD provided some theoretical and experimental guidance for the design and performing the experiments. ZZ, SS and GK recruited the patients and collected the data. XG and JL prepared draft figures and tables. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All authors approve the manuscript for publication.

Ethics approval and consent to participate

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of Hebei Medical University Fourth Affiliated Hospital, and the informed consent was obtained from all of the patients.

Received: 17 September 2016 Accepted: 5 December 2016

References

1. Nagaraja V, Esllick GD. Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2014;5(1):67–76.
2. Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein A, Taylor P, Alisa Goldstein1 and Philip Taylor1 Family history of cancer and risk for esophageal and gastric cancer in Shaxi, China. BMC Cancer. 2009;9:269.
3. Dong Z, Guo W, Guo Y, Kuang G, Yang Z. Concordant promoter methylation of transforming growth factor-beta receptor types I and II occurs early in esophageal squamous cell carcinoma. Am J Med Sci. 2012;343(5):375–81.
4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
5. Sun XB, Liu ZC, Liu SZ, Li BY, Dai DX, Quan PL, Cheng LP, Lu JB. Descriptive analysis of incidence and time trends of esophageal and gastric cancers in Linzhou city, Zhejiang. Zhonghua Zhong Liu Za Zhi. 2007;29(10):764–7.
6. Guohong Z, Min S, Duenmei W, Songnian H, Min L, Jinsong L, Hongbin L, Feng Z, Dongping T, Heling Y, Zhicai L, Shiyong L, Quansheng G, Xiaoyun L, Yuxia G. Genetic heterogeneity of oesophageal cancer in high-incidence areas of southern and northern China. PloS One. 2011;5:e9668.
7. Gao X, Wen J, Zhang L, Li X, Ning Y, Meng A, Chen YG. Dapper1 is a nucleocytoplasmic shuttling protein that negatively modulates wnt signaling in the nucleus. J Biol Chem. 2008;283(51):35679–88.
8. Katoh M, Katoh M. Identification and characterization of human DAPPER1 and DAPPER2 genes in silico. Int J Oncol. 2003;22(4):907–13.
9. Fisher DA, Kivimäe S, Hoshino J, Suriben R, Martin PN, Baxter N, Cheyette BN. Three Dact gene family members are expressed during embryonic development and in the adult brains of mice. Dev Dyn. 2006;235(3):2620–30.
10. Kivimäe S, Yang XY, Cheyette BN. All Dact (Dapper/Frodo) scaffold proteins dimerize and exhibit conserved interactions with Vangl, Dvl, and serpine/threonine kinases. BMC Biochem. 2011;12:33.
11. Cheyette BN, Waxman JS, Miller JR, Takekuma K, Sheldahl LC, Kletetsbova N, Fox EP, Eamet T, Moon RT. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. DevCell. 2002;2(4):449–61.
12. Schubert FA, Sobreira DR, Janousek RG, Alvares LE, Dietrich S. Dact genes are chordate specific regulators at the intersection of Wnt and Tgf-beta signaling pathways. BMC Evol Biol. 2014;14:157.
13. Wang S, Dong Y, Zhang Y, Wang X, Xu L, Yang S, Li X, Dong H, Xu L, Su L, Ng SS, Chang Z, Sung JJ, Zhang X, Yu J. DACT2 is a functional tumor suppressor through inhibiting Wnt/b-catenin pathway and associated with poor survival in colon cancer. Oncogene. 2015;34(20):2575–85.
14. Li X, Florez S, Wang J, Cao H, Amendt BA. Dact2 represses PTX2 transcriptional activation and cell proliferation through Wnt/beta-catenin signaling during odontogenesis. PLoS One. 2013;8:e54868.
15. Zhang X, Yang Y, Liu X, Hemman JG, Brock MV, Lichessi JD, Yue W, Pei X, Guo M. Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma. Epigenetics. 2013;8(4):373–82.
16. Yin X, Xiang T, Li L, Su X, Shu X, Luo X, Huang J, Yuan Y, Peng W, Oberst M, Kelly K, Ren G, Tao Q, DACT1, an antagonist to Wnt/b-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res. 2013;15(2):R23.
17. Ja Y, Yang Y, Brock MV, Zhan Q, Hemman JG, Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signaling pathway in human lung cancer. J Pathol. 2013;230(2):194–204.
18. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, Cheyette BN, Yu Q. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008;13(6):529–41.
19. Schussel JL, Kalinke LP, Sassi LM, de Oliveira BV, Pedruzzi PA, Olandoski M, Alvares LE, Garlet GP, Trevilatto PC. Expression and epigenetic regulation of DACT1 and DACT2 in oral squamous cell carcinoma. Cancer Biomark. 2015;15(1):1–7.
20. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23(1):206–15.
21. Guo W, Wang C, Guo Y, Shen S, Guo X, Kuang G, Dong Z. RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma. Clin Exp Metastasis. 2015;32(1):83–90.
22. Wen D, Zhang N, Shan B, Wang S. Helicobacter pylori infection may be implicated in the topography and geographic variation of upper gastrointestinal cancers in the Taihang Mountain high-risk region in northern China. Helicobacter. 2010;15(S):416–21.
23. Zhang N, Wen D, Shan B, Wang S, Zhang L, Wei L, Zou W, Kitau K, Akazawa K. Clustering and geographic variation of upper gastrointestinal cancers in a
high-risk region of esophageal cancer in northern China. Asian Pac J Cancer Prev. 2011;12(1):193–8.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
25. Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G, Li L, Dai N, Si J, Tao Q, Sung JJ, Yu J. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology. 2011;53(3):843–53.
26. Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y. Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. BJ Cancer. 2001;85(7):1032–6.
27. Li LC, Daihya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–31.
28. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol. 2003;3(3):235–40.
29. Yu Y, Yan W, Liu X, Jia Y, Cao B, Yu Y, Lv Y, Brock MV, Herman JG, Licchesi J, Yang Y, Guo M. DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. Am J Cancer Res. 2014;4(6):710–24.
30. Zhang M, Linghu E, Zhan Q, He T, Cao B, Brock MV, Herman JG, Xiang R, Guo M. Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling. Oncotarget. 2016;7(14):17957–69.
31. Guo W, Dong Z, Guo Y, Chen Z, Kang G, Yang Z. Methylation-mediated repression of GADD45A and GADD45G expression in gastric cancer. Mol Carcinog. 2015;54(12):1722–33.
32. Guo W, Zhang M, Shen S, Guo Y, Kuan G, Yang Z, Dong Z. Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma. Cancer. 2014;120(16):2412–23.
33. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet. 2011;20(22):4299–310.
34. Bai X, Evans J, Chae H, Pilrose J, Kim S, Yan P, Huang RL, Lai HC, Lin H, Liu Y, Miller D, Rhee JK, Huang YW, Gu F, Gray JW, Huang TM, Nephew K. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene. 2013;32(38):4519–28.
35. Deng J, Liang H, Zhang R, Ying G, Xie X, Yu J, Fan D, Hao X. Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer. Am J Cancer Res. 2014;4(5):518–27.
36. Chen SH, Chen SC, Chao YK, Yen TC. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS One. 2013;8:e82812.
37. Sun G, Wang S, Hu X, Su J, Huang T, Yu J, Tang L, Gao W, Wang JS. Fumonisin B1 contamination of home-grown corn in high-risk areas for esophageal and liver cancer in China. Food Addit Contam. 2007;24(3):181–5.

Submit your next manuscript to BioMed Central and we will help you at every step:
- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit